NeoStem, Inc. (AMEX: NBS; Stock Twits: $NBS) is engaged in the development and manufacturing of cell-based therapies in the U.S. Its January 2011 acquisition of Progenitor Cell Therapy, LLC ("PCT") is central to the Company's strategic mission of capturing the paradigm shift to cell therapy.
Robert van den Brink, Goudappel Coffeng. Spreker bij ‘Energietransitie: kansen voor bedrijfsleven en instellingen met Amsterdam Smart City’, 26-10-2011, georganiseerd door KennisKring Amsterdam.
Debt Resolve Inc. (OTCBB: DRSV) is a leading provider of patented online bidding solutions for the settlement and collection of defaulted consumer debt. The company also provides early stage solutions for delinquent debt that has not charged off. Unlike Portfolio Recovery Associates Inc. (NASDAQ: PRAA) and Asset Acceptance Capital Corporation (NASDAQ: AACC), the company does not buy debt but works as a pure play technology company with banks, creditors, law firms and collections agencies to help them more efficiently recover funds.
Robert van den Brink, Goudappel Coffeng. Spreker bij ‘Energietransitie: kansen voor bedrijfsleven en instellingen met Amsterdam Smart City’, 26-10-2011, georganiseerd door KennisKring Amsterdam.
Debt Resolve Inc. (OTCBB: DRSV) is a leading provider of patented online bidding solutions for the settlement and collection of defaulted consumer debt. The company also provides early stage solutions for delinquent debt that has not charged off. Unlike Portfolio Recovery Associates Inc. (NASDAQ: PRAA) and Asset Acceptance Capital Corporation (NASDAQ: AACC), the company does not buy debt but works as a pure play technology company with banks, creditors, law firms and collections agencies to help them more efficiently recover funds.
María montessori. el nino. el secreto de la infanciaAna Otalora
En su libro, Montessori propone una nueva forma de abordar la educación infantil, que tiene como objetivo liberar a características ocultas del niño a través de la observación de los períodos sensibles del niño, la preparación de un entorno libre de obstáculos , y el diseño de programas de formación de profesores adecuados.
Business Intelligence is an everyday tool for managers and engineers to create demand and consumption analysis, cost allocation reports, risk factor calculations,and much more.
More information: http://www.konsys-international.com
Twitter: http://twitter.com/avreporter/
Facebook: http://www.facebook.com/pages/KONsys-Energy-Management/149458798400618
I conference big data_andrew borthowickInteliusGal
This panel will address issues encountered when working with large data sets to bring about information, understanding, meaning and value. It will touch upon databases, sensors, networks, security, privacy, visualization, analytics, search, perceptual & cognitive psychology, business strategy and more.
tweetbook: Digitalna hronika kluba 5/2010 - 10/2014 Дигитална хроника клубаБициклистички клуб ГОРСКИ
http://bkgorski.com/vesti/tweetbook-digitalna-hronika-kluba-52010-102014
28/10/2014 19:31 #whatwereyoudoingat10 from Art Barn http://t.co/crFkhQx1bO #traveltuesday
24/10/2014 08:04 RT @milan_maximo: Od jutros počinjem da vežbam za triatlon, sve sam lepo proverio šta sve treba da pređem da dođem do nje, problem mi je mo…
08/10/2014 15:42 Trening sa ajronmenom | BK Gorski http://t.co/5XS9VChEdo #trening http://t.co/4P70O8p4RD
08/10/2014 15:11 Trening staza: jogging/mtb #Sokobanja #jogging #mtb #trening http://t.co/sBXqhF0jby
08/10/2014 15:06 #trening sa ajronmenom Radetom po oblačnom i vetrovitom Ozrenu: pripreme za maraton u Lozani http://t.co/zH1kO2ZXPw
05/10/2014 22:52 18. Iron Bike Race Einsiedeln | BK Gorski http://t.co/VrueMWnMgd #mtb #marathon #maraton http://t.co/kIoNh0JKU0
04/10/2014 21:26 Danny Macaskill: The Ridge: http://t.co/HciqH5BbXo
04/10/2014 19:23 [Ртањ] #Rtanj #Resnik http://t.co/LjqfAHp1xu
03/10/2014 12:27 /via http://t.co/XgOGNurTxQ ОДРЖАНА ПОСЛЕДЊА РУНДА МТБ КУПА СРБИЈЕ У СОКОБАЊИ, ЂУРЂИЋ ПОТВРДИО ДОМИНАЦИЈУ 28/Сеп/2014 http://t.co/Q2e5ceNEsD
03/10/2014 07:33 ТРОФЕЈ СОКОБАЊА ~ КУП СРБИЈЕ 20140928 СОКО ТВ TV GRAF HD 3GP: http://t.co/fuqaKg4wTY #Sokobanja #video
01/10/2014 08:04 ТРОФЕЈ СОКОБАЊА ~ КУП СРБИЈЕ 20140928 ТВ СОКО HD 3GP: TV GRAF http://t.co/7gigK9WAOr w/ @DjukaMtb23 & @DeMiRmtb http://t.co/PAIjNmZ6Fj
30/09/2014 23:17 MMiiiX http://t.co/HCbfyWaIV9 #MusicMonday #TravelTuesday http://t.co/w94cvlZu77
30/09/2014 19:40 Trofej Sokobanje 2014. by Saša Rajković https://t.co/ONesgw7Fdv #Sokobanja #fotke #photo w/ @DjukaMtb23 http://t.co/ElB1zoo7Ai
30/09/2014 17:12 ТРОФЕЈ СОКОБАЊА - КУП СРБИЈЕ 20140928 ТВ СОКО.mp3 http://t.co/6SqvyYrP6X #Sokobanja #mtb #mp3
30/09/2014 16:27 http://t.co/IVjcfXZ5i1 XCO Soko Banja Animation W/ @DjukaMtb23 & @DeMiRmtb
30/09/2014 08:08 /mt @BikeMagazin: Kup Srbije u Soko Banji by Branko Hajduković, predsednik BSCG http://t.co/FKWel1Boek #mtb #CrnaGora http://t.co/TgfhZoAI18
29/09/2014 14:26 TROFEJ SOKOBANJA 2014 | BK Gorski http://t.co/aR9FyFqtYv #MTB #Srbija #Sokobanja http://t.co/ngi1zUa3Rx
28/09/2014 16:26 Трофеј СОКОБАЊА ~ КУП СРБИЈЕ Старт Полетараца #Sokobanja #mtb #video http://t.co/8TUrCT27eM
24/09/2014 19:53 Zahvalnica PD Oštra Čuka | BK Gorski http://t.co/zcNE5hVJij #Planinari #Sokobanja http://t.co/EXCW0uanVe
24/09/2014 14:44 http://t.co/vu9kJn1P65 - :Do juče sedma, sada, ipak, osma trka MTB Kupa Srbije #8 28.09. Trofej Sokobanja #XCO #GP http://t.co/IH316d5NDB
23/09/2014 16:45 U nedelju, idealni vremenski uslovi za MTB http://t.co/BUDGkPRHFs #Sokobanja СОКОБАЊА http://t.co/zGemmtZVMp
22/09/2014 06:36 Pozdrav sa Dunava | BK Gorski http://t.co/r1T00zQJOQ #Dunav #ribolov http://t.co/6vzenYoJzm
21/09/2014 18:32 БК ГОРСКИ учествовао је у 4. по реду планинарској акцији О�
LifeTech Capital Updates NeoStem (NBS) Strong Buy $4.00 Target. New York, NY-based NeoStem is a multi-faceted, multinational medical company. Among their business are adult stem cell collection, processing and storage in the U.S., research and development for diagnostic and therapeutic applications using autologous adult stem cells, including their VSEL™ technology (very small embryonic-like stem cells) and several China-based, adult stem cell therapeutics operational and R&D activities for adult stem cell therapeutics focused on regenerative medicine. In addition, NeoStem and the Vatican's Pontifical Council for Culture announced a joint initiative with their charitable foundations to expand research and raise awareness of adult stem cell therapies. A 3-day international conference at the Vatican on adult stem cell research, including VSEL™ technology, is planned for 2011 and will focus on medical research presentations and theological and philosophical considerations and implications of scientific achievements.
NeoStem, Inc. (AMEX: NBS; Stock Twits: $NBS) is engaged in the development and manufacturing of cell-based therapies in the U.S. Its January 2011 acquisition of Progenitor Cell Therapy, LLC ("PCT") is central to the Company's strategic mission of capturing the paradigm shift to cell therapy. The acquisition of PCT gives NeoStem not only access to a world class contract manufacturing cell therapy company but provides a platform and expertise around the evaluation, development and regulatory requirements to develop autologous, allogeneic, immunomodulatory and vaccine-based therapeutics. NeoStem also holds the worldwide exclusive license to VSEL(TM) Technology, which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use.
Headquartered in San Francisco, JMP Securities was founded in January 2000 in response to the consolidation of established independent research boutiques by large commercial banks. Since the mid-1990s nearly 50 regional investment banks—including San Francisco’s Montgomery Securities, Hambrecht & Quist and Robertson Stephens—have been acquired by major financial institutions. Such industry consolidation has pressured a new breed of bulge-bracket investment banks to compete for large market-capitalization clients and has greatly reduced Wall Street’s focus on the middle market. JMP Securities was formed in the mold of its independent, research-driven predecessors as a growth-oriented, entrepreneurial firm dedicated to serving the needs of small and midsized companies and the institutions that invest in them.
María montessori. el nino. el secreto de la infanciaAna Otalora
En su libro, Montessori propone una nueva forma de abordar la educación infantil, que tiene como objetivo liberar a características ocultas del niño a través de la observación de los períodos sensibles del niño, la preparación de un entorno libre de obstáculos , y el diseño de programas de formación de profesores adecuados.
Business Intelligence is an everyday tool for managers and engineers to create demand and consumption analysis, cost allocation reports, risk factor calculations,and much more.
More information: http://www.konsys-international.com
Twitter: http://twitter.com/avreporter/
Facebook: http://www.facebook.com/pages/KONsys-Energy-Management/149458798400618
I conference big data_andrew borthowickInteliusGal
This panel will address issues encountered when working with large data sets to bring about information, understanding, meaning and value. It will touch upon databases, sensors, networks, security, privacy, visualization, analytics, search, perceptual & cognitive psychology, business strategy and more.
tweetbook: Digitalna hronika kluba 5/2010 - 10/2014 Дигитална хроника клубаБициклистички клуб ГОРСКИ
http://bkgorski.com/vesti/tweetbook-digitalna-hronika-kluba-52010-102014
28/10/2014 19:31 #whatwereyoudoingat10 from Art Barn http://t.co/crFkhQx1bO #traveltuesday
24/10/2014 08:04 RT @milan_maximo: Od jutros počinjem da vežbam za triatlon, sve sam lepo proverio šta sve treba da pređem da dođem do nje, problem mi je mo…
08/10/2014 15:42 Trening sa ajronmenom | BK Gorski http://t.co/5XS9VChEdo #trening http://t.co/4P70O8p4RD
08/10/2014 15:11 Trening staza: jogging/mtb #Sokobanja #jogging #mtb #trening http://t.co/sBXqhF0jby
08/10/2014 15:06 #trening sa ajronmenom Radetom po oblačnom i vetrovitom Ozrenu: pripreme za maraton u Lozani http://t.co/zH1kO2ZXPw
05/10/2014 22:52 18. Iron Bike Race Einsiedeln | BK Gorski http://t.co/VrueMWnMgd #mtb #marathon #maraton http://t.co/kIoNh0JKU0
04/10/2014 21:26 Danny Macaskill: The Ridge: http://t.co/HciqH5BbXo
04/10/2014 19:23 [Ртањ] #Rtanj #Resnik http://t.co/LjqfAHp1xu
03/10/2014 12:27 /via http://t.co/XgOGNurTxQ ОДРЖАНА ПОСЛЕДЊА РУНДА МТБ КУПА СРБИЈЕ У СОКОБАЊИ, ЂУРЂИЋ ПОТВРДИО ДОМИНАЦИЈУ 28/Сеп/2014 http://t.co/Q2e5ceNEsD
03/10/2014 07:33 ТРОФЕЈ СОКОБАЊА ~ КУП СРБИЈЕ 20140928 СОКО ТВ TV GRAF HD 3GP: http://t.co/fuqaKg4wTY #Sokobanja #video
01/10/2014 08:04 ТРОФЕЈ СОКОБАЊА ~ КУП СРБИЈЕ 20140928 ТВ СОКО HD 3GP: TV GRAF http://t.co/7gigK9WAOr w/ @DjukaMtb23 & @DeMiRmtb http://t.co/PAIjNmZ6Fj
30/09/2014 23:17 MMiiiX http://t.co/HCbfyWaIV9 #MusicMonday #TravelTuesday http://t.co/w94cvlZu77
30/09/2014 19:40 Trofej Sokobanje 2014. by Saša Rajković https://t.co/ONesgw7Fdv #Sokobanja #fotke #photo w/ @DjukaMtb23 http://t.co/ElB1zoo7Ai
30/09/2014 17:12 ТРОФЕЈ СОКОБАЊА - КУП СРБИЈЕ 20140928 ТВ СОКО.mp3 http://t.co/6SqvyYrP6X #Sokobanja #mtb #mp3
30/09/2014 16:27 http://t.co/IVjcfXZ5i1 XCO Soko Banja Animation W/ @DjukaMtb23 & @DeMiRmtb
30/09/2014 08:08 /mt @BikeMagazin: Kup Srbije u Soko Banji by Branko Hajduković, predsednik BSCG http://t.co/FKWel1Boek #mtb #CrnaGora http://t.co/TgfhZoAI18
29/09/2014 14:26 TROFEJ SOKOBANJA 2014 | BK Gorski http://t.co/aR9FyFqtYv #MTB #Srbija #Sokobanja http://t.co/ngi1zUa3Rx
28/09/2014 16:26 Трофеј СОКОБАЊА ~ КУП СРБИЈЕ Старт Полетараца #Sokobanja #mtb #video http://t.co/8TUrCT27eM
24/09/2014 19:53 Zahvalnica PD Oštra Čuka | BK Gorski http://t.co/zcNE5hVJij #Planinari #Sokobanja http://t.co/EXCW0uanVe
24/09/2014 14:44 http://t.co/vu9kJn1P65 - :Do juče sedma, sada, ipak, osma trka MTB Kupa Srbije #8 28.09. Trofej Sokobanja #XCO #GP http://t.co/IH316d5NDB
23/09/2014 16:45 U nedelju, idealni vremenski uslovi za MTB http://t.co/BUDGkPRHFs #Sokobanja СОКОБАЊА http://t.co/zGemmtZVMp
22/09/2014 06:36 Pozdrav sa Dunava | BK Gorski http://t.co/r1T00zQJOQ #Dunav #ribolov http://t.co/6vzenYoJzm
21/09/2014 18:32 БК ГОРСКИ учествовао је у 4. по реду планинарској акцији О�
LifeTech Capital Updates NeoStem (NBS) Strong Buy $4.00 Target. New York, NY-based NeoStem is a multi-faceted, multinational medical company. Among their business are adult stem cell collection, processing and storage in the U.S., research and development for diagnostic and therapeutic applications using autologous adult stem cells, including their VSEL™ technology (very small embryonic-like stem cells) and several China-based, adult stem cell therapeutics operational and R&D activities for adult stem cell therapeutics focused on regenerative medicine. In addition, NeoStem and the Vatican's Pontifical Council for Culture announced a joint initiative with their charitable foundations to expand research and raise awareness of adult stem cell therapies. A 3-day international conference at the Vatican on adult stem cell research, including VSEL™ technology, is planned for 2011 and will focus on medical research presentations and theological and philosophical considerations and implications of scientific achievements.
NeoStem, Inc. (AMEX: NBS; Stock Twits: $NBS) is engaged in the development and manufacturing of cell-based therapies in the U.S. Its January 2011 acquisition of Progenitor Cell Therapy, LLC ("PCT") is central to the Company's strategic mission of capturing the paradigm shift to cell therapy. The acquisition of PCT gives NeoStem not only access to a world class contract manufacturing cell therapy company but provides a platform and expertise around the evaluation, development and regulatory requirements to develop autologous, allogeneic, immunomodulatory and vaccine-based therapeutics. NeoStem also holds the worldwide exclusive license to VSEL(TM) Technology, which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use.
Headquartered in San Francisco, JMP Securities was founded in January 2000 in response to the consolidation of established independent research boutiques by large commercial banks. Since the mid-1990s nearly 50 regional investment banks—including San Francisco’s Montgomery Securities, Hambrecht & Quist and Robertson Stephens—have been acquired by major financial institutions. Such industry consolidation has pressured a new breed of bulge-bracket investment banks to compete for large market-capitalization clients and has greatly reduced Wall Street’s focus on the middle market. JMP Securities was formed in the mold of its independent, research-driven predecessors as a growth-oriented, entrepreneurial firm dedicated to serving the needs of small and midsized companies and the institutions that invest in them.
Powerful Medical Branding for Your Medical Device Investor Deck. Example: Amnis Therapeutics Investor Deck by Berliner Design (www.berlinerdesign.co.il).
Pharma leader series top stem cell technology companies 2015 2025Visiongain
For an Executive Summary of this report please contact ben.suntivarakom@visiongain.com
(+44 (0)20 7549 9976)
or refer to our website: http://goo.gl/bhNICQ
In a world where medical software is systemically plagued by complexity, OMS is helping cardiologists take back control. Created by and for cardiologists, allow us to restore your faith in what's possible.
This innovative heart implant concept, was not designed to extend the normal life cycle, but to transform the lives of thousands of patients whose only hope has been a transplantation.
Caprock: "We are initiating coverage on Pegasi Energy Resources Corporation with a
STRONG BUY rating and with a 12-month price target of $1.50. We believe PGSI’s shares offer investors a unique and favorable risk/reward profile."
FORM 8-K. Filed 05/07/12 for the Period Ending 05/07/12. A PowerPoint presentation that Ventrus Biosciences, Inc. will present at the 37th Annual Deutsche Bank Health Care Conference in Boston, MA on Monday, May 7, 2012.
Sections include: Company Overview --- Focus on Fibromyalgia and Post-Traumatic Stress Disorder. Large Markets with Unmet Need --- Novel Formulation Technology Applied to Known Ingredients = Better Drugs --- Robust Product Pipeline with Nearterm Milestones, and more.
Early this morning, SunSi announced it is acquiring 51% of
TransPacific Energy, Inc., a U.S.-based company that
designs and sells energy systems which maximize heat
recovery and convert waste heat into electrical energy.
APDN sells patented DNA security solutions to protect products, brands and intellectual property from counterfeiting and diversion. SigNature DNA is a botanical mark used to authenticate products in a unique manner that essentially cannot be copied. Our mark provides a forensic chain of evidence that can be used to prosecute perpetrators. To learn more, go to www.adnas.com where APDN routinely posts all press releases.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Temporomandibular Joint By RABIA INAM GANDAPORE.pptx
Neostem, Inc. ($NBS) - WBB Securities Report
1. WBB Securities, LLC
Stephen G. Brozak sbrozak@wbbsec.com (908) 518-7610
Neostem, Inc. (NBS) (08/16/2011)
Upgrading from Hold to Speculative Buy and adjusting Price Target to $1.40
Rating Legend:
Strong Buy-Should be aggressively purchased.
Buy-Should be purchased on market weakness.
Hold-Fairly valued.
Sell-Stock should be sold on market strength.
Sell Short-Should be aggressively sold.
Speculative Buy – For aggressive accounts
Current Price $0.74
12-Month Trading Range $0.60-$2.15
Market Capitalization (Mil) $69.56
Shares Outstanding (Mil) 94.00*
12-Month Price and Trading Volume Avg. Daily Volume 464,966
L. T. Debt (Mil) $5.9
You Gotta Have Heart Dividend/Yield N/A
On July 14, 2011, NeoStem, Inc. (NBS) announced an Book Value P/S 0.83
agreement to acquire Amorcyte, Inc., a company focusing
on discovering novel treatments for cardiovascular NASDAQ Composite 2,555.20
disease. Amorcyte’s lead product candidate, AMR-001, S&P 500 1,204.49
has completed a Phase I study of acute myocardial 12 Month Target Price $1.40
infarction (AMI) patients and expects to begin a Phase II Source: QUODD
*146 Million Shares Fully Diluted
study by 1Q 2012 or earlier with a mid 2013 readout of Cash EPS 2010 2011 2012
results. Q1 (0.12)A (0.14)A
Q2 (0.11)A (0.13)A
AMR-001 consists of a patient’s own bone marrow cells
Q3 (0.13)A
(bone-marrow derived mononuclear cells), processed in
Q4 (0.10)A
facilities of Progenitor Cell Therapy, LLC (an NBS-owned Year (0.46)A (0.55)E (0.44)E
subsidiary) to create CD34+CXCR4+-rich pharmaceutical-
grade cells. These cells are reinjected through coronary P/E NM NM NM
arteries into damaged areas of the heart 6 to 11 days after EPS Growth NM NM NM
the patient experiences an (AMI). The CD34+ cells are FY Rev. (Mil) 69.8A 10.0E** 15.0E**
**Exclusive of
then able to have an anti-apoptotic effect in addition to a FY:DEC Suzhou Erye Revs
See Page 4 for Management Biographies
positive angiogenic effect in the area around the infracted
tissue (the peri-infarct zone). The CXCR4 receptors on the cells allow them to home in on areas that
are ischemic, thus allowing the cells to concentrate where needed rather than randomly disperse
throughout the bloodstream. This is essentially a mechanism for damage control, in which the heart
can preserve as much viable tissue as possible, and in doing so, prevent the classic progression to
Congestive Heart Failure and death that is seen in severe heart attack patients. This is a one-time
treatment that holds promise to reduce continuing damage to heart muscle after an AMI, to reduce
patient care cost over time and to improve quality of life for those patients who are significantly
affected by ischemic heart disease.
2. NBS’s product has particular promise given that it is an autologous product, and thus avoids the many
negative consequences that plague allogeneic products. AMR-001’s administration is worth
highlighting. First, it utilizes the homing potential granted by the CXCR4 receptors, allowing for a larger
percentage of cells to remain where they can be effective. Second, AMR-001 is administered via the
IRA (Infarct Related Artery), and thus is performed in an identical manner as the original coronary
cauterization. This allows for ease of use, consistent deployment of cells and avoids the potential risks
arising from intra-cardiac injections of cells.
NBS has conducted favorable phase I clinical trials that make AMR-001 an ideal candidate for further
trials. The company has a well thought out phase II clinical trial planned that is intended to show clear
clinical efficacy in enrolled patients.
Heart disease is the leading cause of death in the United States. Over 1 million Americans suffer AMIs
each year, with a significant proportion of them having significant cardiac dysfunction. This number is
expanded many fold when international markets are considered. Thus we believe AMR-001 has
potential to serve a large worldwide population. Given the grim statistics of AMIs in the U.S. and the
promise of AMR-001 to provide benefit to these patients, we are raising our rating on NBS to
Speculative Buy with a 12-Month Price Target of $1.40
AMR-001 Trials
Phase I Study
The Phase I study was conducted by the Emory University School of Medicine under Principal
Investigator Dr. Arshed Quyummi, M.D., Professor of Medicine and Cardiology. This study
performed autologous intracoronary infusions of bone-marrow derived CD34+ cells in patients with
significant cardiac dysfunction post-STEMI. Treatment was administered in the golden period of 6
to 9 days after infarct-related artery stent placement. Patients were dosed at four dose levels in this
safety and tolerability study. The secondary objective of the study was to assess the effect on
cardiac function and cardiac perfusion in the infarcted area.
Primary outcome measures for the Phase I study were cardiac function at two time points (3 and 6
months follow-up), compared to baseline measures obtained prior to CD34+ cell product infusion.
Secondary outcome measures include perfusion of the infarct region at 6 months follow-up
compared to baseline measures obtained prior to CD34+ cell product infusion. The study also
established a threshold dose of 10 million cells injected per patient.
Inclusion criteria were:
Patients age 18 - 75 years
Acute ST elevation myocardial infarction meeting ACC/AHA criteria, with symptoms of chest
pain within 3 days of admission. Criteria include ST elevation > 1mm in limb leads or 2 mm
in two or more precordial leads and increased levels of troponin, CPK MB or both)
NYHA heart failure class of I, II or III
2
3. Phase II Study
The Phase II trial will include 150 patients, 75 of whom will be treated with AMR-001 and 75 will
receive a placebo. To be a candidate for this trial, the patient must have had experienced a STEMI,
have undergone cardiac stent placement (which is standard of care), and after 96 hours have
undergone a cardiac magnetic resonance exam that demonsrates an ejection fraction of less than
or equal to 48 percent in addition to abnormal cardiac wall motion.
Treated patients will receive a dose greater than 10 million cells, two to four-times the threshold
dose established in the Phase I trial. Of note, treatment doses of up to 5 to 10 times that amount
are permitted by FDA in this study.
The study is expected to be completed in one year and will measure clinically-significant end-points.
Six month measurements will include coronary perfusion, preservation of heart muscle function and
quality of life. In years one, two and three, patients will be followed for major cardiac events,
including heart failure, myocardial infarction and death.
AMR-001’s phase II trial will be considered successful if positive end-points of heart function are
observed. These will be quantified by maintenance of ejection fraction, improved wall motion,
increased myocardial contractility, and improved heart volumes in the treated group versus the
control group. This should also be met by improvement in quality of life (QoL) without safety signals.
Should all measures trend positively NeoStem hopes to initiate a pivotal study prior to 2 and 3 year
MACE read-outs upon which point a Phase II/III study may qualify as a supporting trial for approval.
Other NBS Initiatives
In addition to AMR-001, NBS operates within three distinct business segments: the U.S. market for
adult stem cells, the China market for adult stem cells, and the China market for pharmaceuticals.
U.S. Adult Stem Cells
In the U.S., NBS provides stem cell collection, processing and storage services through a network
of centers primarily in the Southern California and Northeastern U.S. NBS allows healthy individuals
to donate their own stem cells to be used therapeutically later in life. The therapeutic applications for
which the stem cells would be used are under each collection center’s discretion. NBS does not
participate in any clinical decision-making in the U.S. Progenitor Cell Therapy; LLC provides the
commercial collection and processing services.
On April 27, 2010, NBS announced the launch of a new adult stem cell collection center and
research and development laboratory in Cambridge, Massachusetts. The company now has a
network of collection centers in the U.S.
NBS licensed Very Small Embryonic-Like (VSEL) technology from the University of Louisville to
research and develop potential diagnostic and therapeutic products based on very small embryonic-
like stem cells, found in bone marrow. The company believes vast therapies could be developed
from VSEL technology including those for cardiovascular, neural and ophthalmic diseases. VSEL
technology holds the promise as a naturally pluripotent cell and has the potential to move the
regenerative adult stem cell space to the next level of therapeutic value.
3
4. China Adult Stem Cells
NBS’s Chinese adult stem cell efforts include creating a separate China-based stem cell operation,
constructing a new research and development laboratory and processing facility in Beijing that will
compliment PCT’s CMO operations as well. In addition, NBS is today providing stem cell therapies
to a network of hospitals and obtaining stem cell product licenses in regenerative medicine.
To develop its regenerative medicine pipeline in China, NBS acquired an exclusive license in Asia
from Regenerative Sciences, Inc. for a procedure called Regenexx™. The Regenexx procedure
involves extracting mesenchymal stem cells from the bone marrow to potentially treat various
musculoskeletal diseases. The company has partnered with Shandong Wendeng Orthopedic
Hospital to treat patients with adult stem cell therapies and conduct clinical research in orthopedic
applications.
NBS has also in-licensed certain technologies from Vincent Giampapa, M.D. for skin rejuvenation
therapies based on autologous adult stem cells. The company intends to eventually launch a range
of anti-aging and cosmetic applications in China.
China Pharmaceuticals
In October 2009, NBS completed a merger China Biopharmaceuticals Holdings, Inc., and as a
result, acquired a 51 percent stake in Suzhou Erye Pharmaceuticals Company Ltd. Erye is a
Chinese pharmaceutical company primarily focused on the manufacturing and distribution of
generic antibiotic products throughout China.
Valuation
Our valuation of NBS is based on a sum of the parts analysis. We believe NBS’s greatest asset is
its Amorcyte Phase II clinical technology at $100M. We also believe that the Suzhou Erye
Pharmaceuticals assets have a value of $30M at a minimum. Using a three-times sales model for
Progenitor Cell Therapy, we add an additional $30M. We use a value of $20M for the NBS (VSEL)
technology and finally a $20M price for both cash and remaining assets. Assuming a fully diluted
share count of 146 million shares, we arrive at our adjusted 12-month price target of $1.40 per
share.
Management Biographies
Robin L. Smith – Chairman & CEO, M.D., MBA, joined as Chairman of the Advisory Board in
September 2005 and, effective June 2, 2006, became the Chief Executive Officer and Chairman of
the Board. Dr. Smith received a medical degree from Yale University and a master’s degree in
business administration from the Wharton School. From 2000 to 2003, Dr. Smith served as
President and Chief Executive Officer of IP2M, a multi-platform media company specializing in
healthcare. From 1998 to 2000, she was Executive Vice President and Chief Medical Officer for
HealthHelp, Inc., a National Radiology Management company. She currently serves on the Board
of Trustees of the NYU Medical Center Board, is a member of the Board of Directors for the New
York University Hospital for Joint Diseases, and serves on the Board of Choose Living. Dr. Smith is
the President and serves on the Board of Directors of The Stem for Life Foundation.
4
5. Larry A. May, Chief Financial Officer since January 2006. Mr. May, joined Neostem in
September 2003 to assist with licensing activities. He worked for Amgen from 1983 until 1998 in
several positions of increasing responsibility, becoming Vice President/Treasurer in 1997. From
1998 to 2000, Mr. May served as the Senior Vice President, Finance and Chief Financial Officer of
Biosource International, Inc. From 2000 to 2003, Mr. May served as the Chief Financial Officer of
Saronyx, Inc. From August 2003 to January 2005, Mr. May served as the Chief Financial Officer of
NS California. In March 2005, Mr. May was appointed CEO of NS California and in May 2005 he
was elected to the Board of Directors of NS California. He received a Bachelor of Science degree in
Business Administration & Accounting in 1971 from the University of Missouri.
Catherine M. Vaczy, Vice President and General Counsel since April 2005. From 1997 through
2003, Ms. Vaczy held various senior positions at ImClone Systems Incorporated, most recently as
its Vice President, Legal and Associate General Counsel. From 1988 through 1996, Ms. Vaczy
served as a corporate attorney at the New York City law firm of Ross & Hardies. Ms. Vaczy is
Secretary and serves on the Board of Directors of The Stem for Life Foundation. Ms. Vaczy
received a Bachelor of Arts degree in 1983 from Boston College and a Juris Doctor from St. John’s
University School of Law in 1988.
Jason Kolbert, Vice President of Strategic Business Development, MBA was formerly a
managing director of National Securities where he founded the firm's biotechnology research effort.
He spent the past 16 years on Wall Street as an analyst, both managing biotechnology dedicated
investments (buy-side) and covering biotechnology companies (sell-side). Prior to his career on
Wall Street he spent several years in the pharmaceutical industry with Schering-Plough in Japan.
Mr. Kolbert has an undergraduate degree in Chemistry (New Paltz) and an MBA in Finance
(University of New Haven).
Ian Zhang, President of NeoStem China and Managing Director since September 2010. He
held management and scientific positions in healthcare and biotechnology industries for the past
ten years. Since January 2008, he held the position of Head of Corporate Development and Head
of Integration for Asia Pacific at the Life Technology Corporation. In those positions, Mr. Zhang was
responsible for strategic initiatives in the region to build capabilities and capture growth, identifying
key investment markets in China and other regions, and managing acquisition and integration.
Before that, he was President and General Manager of Dynal Biotech (Beijing) Ltd, a wholly owned
subsidiary of Invitrogen serving the clinical transplant diagnostic market as well as medical research
institutions and government agencies. Mr. Zhang holds a Ph. D. in biotechnology from Simon
Fraser University and a MBA from the University of Chicago.
Andrew L. Pecora, Chief Medical Officer, Progenitor Cell Therapy, M.D., F.A.C.P. since March
1999. He is scheduled to join the Board of Directors for NeoStem pending Board approval. Dr.
Pecora currently serves as Vice President of Cancer Services and Chief Innovations Officer of the
John Theurer Cancer Center at Hackensack University Medical Center, and Co-Managing Partner
of the Northern New Jersey Cancer Center (NNJCC), which is a private physicians practice group
affiliated with HUMC.
Dr. Pecora currently serves as Chairman of the Board of Directors of Tetralogics, a private venture
funded Biotechnology Company developing small molecules for cancer therapy and on the Board
of directors of Cancer Genetics, a private venture funded cancer Diagnostics Company. Dr. Pecora
is a Professor of Medicine at the University of Medicine and Dentistry of New Jersey. He serves on
5
6. the Board of Directors for the American Society for Blood and Marrow Transplantation. In addition,
he has also served on the Board of Directors for the International Society of Hematotherapy and
Graft Engineering, now the International Society for Cellular Therapy; the Accreditation Committee
of the Affiliated Physicians Network; and as an Inspector for the Foundation for Accreditation of
Hematopoietic Cell Therapy.
Dr. Pecora received his medical degree from the University of Medicine and Dentistry of New
Jersey, graduating with honors. He went on to complete his medical education in internal medicine
at New York Hospital and in hematology and oncology at Memorial Sloan-Kettering Cancer Center,
both in New York City. He is board certified in internal medicine, hematology, and oncology.
Robert A. Preti, President and Chief Scientific Officer, Progenitor Cell Therapy, Ph.D. since
March 1999. Dr. Preti is PCT's Co-Founder, President, and Chief Scientific Officer, and a member
of the Company's Board of Managers. Previous positions held by Dr. Preti include Scientific and
Laboratory Director of Hackensack University Medical Center's stem cell processing and research
laboratory and Scientific Director of the Clinical Services Division at the New York Blood Center.
Dr. Preti is a founding member of the International Society for Cellular Therapies, formerly the
International Society for Hematotherapy and Graft Engineering, served on its Executive Committee
and Board of Directors for 10 years, and serves on the Editorial Board for the society’s
journal, Cytotherapy. He currently serves in his fourth term as Director for the AABB. Dr. Preti
received his Doctor of Philosophy degree from New York University, graduating with distinction.
6
7. Distribution of Ratings and Disclosure of Banking Relationships: The following table shows WBB’s
ratings distribution expressed as a percentage of all securities rated as of the end of the most
recent calendar quarter, as well as the percentage of subject companies within each rating category
for whom WBB has provided investment banking services within the previous 12 months.
Percentage of Percentage of
Covered Securities Banking Clients
Buy 68.4% 11.5%
Hold 10.5% 0%
Sell 21.1% 0%
The research analyst who is primarily responsible for the research contained in this research
report and whose name is listed on this report: (1) attest that all of the views expressed in this
research report accurately reflect that of the research analysts' personal views about any and all
of the securities and issuers that are the subject of this research report; and (2) attest that no part
of the research analysts' compensation was, is, or will be, directly or indirectly, related to the
specific recommendations or views expressed by the research analysts in this research report.
All WBB Securities, LLC ("WBB") employees, including research associates, receive
compensation that is based in part upon the overall performance of the firm, including revenues
generated by WBB's investment banking department, but not directly related to those revenues.
Although information herein has been obtained from sources believed to be reliable, we do not
guarantee its accuracy, completeness or fairness. Opinions and estimates may be changed or
withdrawn without notice. This report is not intended as an offer or solicitation, or as the basis for
any contract, for the purchase or sale of any security, loan or other instrument. We or our
affiliates or persons associated with us or such affiliates (“Associated Persons”) do not now, but
may in the future: maintain a long or short position in securities, loans or other instruments
referred to herein or in other securities, loans or instruments of issuers named herein, or in
related derivatives; purchase or sell, make a market in, or buy or sell on a principle basis, or
engage in other transactions involving such securities, loans or instruments of such issuers;
and/or provide investment banking, credit, or other services to any issuers named herein. The
authors of this report and the officers of WBB do not now, but may in the future own options,
rights or warrants to purchase any of the securities of the issuer whose securities are
recommended, unless the extent of ownership is nominal. The past performance of securities,
loans or other instruments does not guarantee or predict future performance. This report may
not be reproduced or circulated without our written authority.
7